Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opening Session Panel Discussion

Advertisement

Advertisement




Sep
08
Today In Oncology
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Duane Mitchell Named Director of the UF Health Cancer Institute
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo